PRPH, US74345W2070

ProPhase Labs stock gained 100 percent despite Q2 revenue decline

Published on 10/05/2026 at 12:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ProPhase Labs stock was last at USD 0.02 on October 2, 2026, after a 100 percent session gain. Q2 revenue fell 29.4 percent year over year.

PRPH, US74345W2070, Illustration mit AI erstellt.

ProPhase Labs stock (ISIN US74345W2070) was last at USD 0.02 on Nasdaq on October 2, 2026, at 4:00 p.m. ET, up 100 percent during the session. The move came as the company reported a weak second quarter, with revenue falling 29.4 percent year over year to USD 1.0 million.

Q2 revenue fell 29.4 percent

According to ToAlpha in its Q2 2026 financial summary, revenue was USD 1.0 million for the quarter ended June 30, 2026, down 29.4 percent from the comparable period. The same summary lists diluted EPS at negative USD 0.22 and a gross margin of 22.4 percent.

The company’s investor-relations page identifies Q2 2026 as its latest financial-results period and links the corresponding 10-Q filing, while describing ProPhase Labs as a biotech, genomics and consumer-products company, according to ProPhase Labs.

Operating loss reached USD 2.6 million

ProPhase Labs reported a Q2 operating loss of USD 2.6 million and a net loss of USD 3.1 million. Operating cash flow was negative USD 78,000 in the quarter, while cash and cash equivalents stood at USD 20,000 on June 30, 2026.

The comparison with the first quarter shows a narrower net loss but lower revenue. Q1 revenue was USD 1.2 million, operating loss was USD 2.4 million and net loss was USD 5.2 million, making revenue the clearest near-term operating pressure point.

Stock doubled in the October 2 session

Trading activity was elevated relative to the company’s small market value. ProPhase Labs stock was last at USD 0.02, with a session low of USD 0.01, a session high of USD 0.02 and volume of 530,584 shares on October 2, 2026.

Market value remains very small

ProPhase Labs had a market capitalization of USD 280.3 thousand on October 2, 2026. Its 52-week range was USD 0.01 to USD 6.70, placing the last price near the lower end of that span and keeping the Q2 revenue trend central to any valuation discussion.